Rigor Reviewed

Rigor-Reviewed Manuscript

Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.

Name: Αlpha¹ Rigor Record — Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.
Item: Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.
Rating: 100
Author: Αlpha¹

Jelen LA, Lythgoe DJ, Stone JM, Young AH, Mehta MA

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 0 high issues for “Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 33 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-designed, rigorously reported randomized crossover trial with strong methodological transparency, including detailed randomization, blinding, ethics, and data/code sharing. Minor gaps include the absence of a formal power analysis and explicit reporting guideline, plus a few copyedit typos.

Both reviewers classified the study as interventional; no divergence. The evaluation covered the full text, with verification components for citations (73 checked, none flagged), statistics (31 tests recomputed consistently), reproducibility (OSF link live), and preregistration (ClinicalTrials.gov). Non-applicable sub-criteria (e.g., animal housing, cell lines) were excluded.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 31 tests: 31 consistent, 0 inconsistent; 29 recomputed directly from the reported test statistics, 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites numerous prior studies on ketamine's mechanism, opioid interactions, and the specific hypothesis that naltrexone attenuates ketamine's effects. It acknowledges limitations of prior clinical studies (small sample sizes, lack of mechanistic exploration) and addresses them by using a larger sample and functional MRS to measure glutamatergic dynamics. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking opioid modulation to ketamine's glutamatergic and antidepressant effects.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Ketamine, a dissociative anesthetic and uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist, has emerged as a new treatment for major depressive disorder (MDD).”

direct quote[Introduction, paragraph 3]

“Importantly, these clinical studies have been limited by small sample sizes and did not explore mechanisms underlying any potential opioid-mediated effects.”